Supporting a potential therapeutic relevance in PD, overexpression of PGC-1α demonstrated neuroprotection against α-synuclein- and rotenone-induced toxicity in vitro [116] and in a parkin interacting substrate (PARIS) overexpression model of PD in vivo [118]. This evidence concerns the gene PPARGC1A and Parkinson disease.